Contemporary management of uterine fibroids: focus on emerging medical treatments

Abstract

Objective:

This review provides an overview of therapeutic options, with a specific focus on the emerging role of medical options for UF management.

Research design and methods:

PubMed, Google Scholar, and Cochrane Systematic Reviews were searched for articles published between 1980 and 2013. Relevant articles were identified using the following terms: ‘uterine fibroids’, ‘leiomyoma’, ‘heavy menstrual bleeding’, and ‘menorrhagia’. The reference lists of articles identified were also searched for other relevant publications.

Results:

Because of the largely benign nature of UFs, the most conservative options that minimize morbidity/risk and optimize outcomes should be considered. Watchful waiting, or no immediate intervention combined with regular follow-up, is an appropriate option for the majority of UF patients who experience no symptoms. For women with symptomatic UFs, the optimal treatment should restore quality of life through rapid relief of UF signs and symptoms, reduce tumor size for a sustained period, and maintain or improve fertility. Invasive surgical treatments, such as hysterectomy, have historically been the mainstay of UF treatment. Less invasive surgical and interventional techniques, such as myomectomy, uterine artery embolization, endometrial ablation, and myolysis provide alternatives to hysterectomy. Until recently, medical management of UFs was characterized by short-term treatments and therapies that provided symptomatic control. In addition to controlling abnormal uterine bleeding, newer medical therapies, including the recently Health-Canada-approved ulipristal acetate, act directly to shrink the tumor. Although no agent is currently approved for such use, emerging evidence suggests the potential for long-term medical management of UFs.

Conclusions:

The advent of novel medical therapies may diminish the long-held reliance on more invasive surgical UF treatment options.

Keywords: :

• Heavy menstrual bleeding
• Medical management
• Ulipristal acetate
• Uterine fibroids

View correction statement:

Erratum

Transparency

Declaration of funding

Editorial support for this review was funded by Actavis Canada.

Declaration of financial/other relationships

S.S.S. has disclosed that he is on the speaker bureau for Abbvie Corporation, Actavis, Bayer Canada, and Ethicon Endosurgery. He also has ongoing research grants with Abbvie Corporation. L.B. has disclosed that she is on the speaker bureau for Abbvie Corporation, Actavis, Bayer Canada and Olympus Canada.

Acknowledgments

The authors thank Actavis Canada for their support of this project from its inception and also Peter Janiszewski PhD and John Ashkenas PhD, both of SCRIPT in Toronto, ON, for editorial assistance.